Sign In
Buy SLRX
$0.84
+0 (+0%)
At Close: Apr 14, 2026
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
08:00am, Friday, 12'th May 2023
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer t
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
08:00am, Thursday, 11'th May 2023
FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to discuss future development and potential registration pathways
Salarius Pharmaceuticals Inc.'s stock SLRX soared 33% in premarket trade Tuesday after the company said the U.S. Food and Drug Administration has lifted a partial clinical hold on a trial of a treatme
Decision Follows Review of Comprehensive Safety Data Package Submitted by the Company Salarius Plans to Meet with FDA to Discuss Future Development and Potential Registration Pathways HOUSTON, May 09,
Submission of Investigational New Drug application expected in the second quarter of 2023 with start of Phase 1 trial expected in second half of 2023 Submission of Investigational New Drug application
SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity in animal models of multiple myeloma
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference
04:02pm, Tuesday, 04'th Apr 2023
HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
08:30am, Monday, 27'th Mar 2023
Data to be presented at AACR demonstrate significant SP-3164 anticancer activity in both non-Hodgkin Lymphoma and Multiple Myeloma cell lines and animal models
Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting
11:00am, Wednesday, 15'th Mar 2023
HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer
Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas
08:30am, Thursday, 16'th Feb 2023
HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc . (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer
Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
08:30am, Friday, 27'th Jan 2023
Preclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin's lymphomas, and significantly better performance than standard-of-care treatment
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models
Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine
Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference
08:30am, Wednesday, 19'th Oct 2022
HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer
Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference
12:00pm, Tuesday, 20'th Sep 2022
HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of n
